Recombinant human C1 esterase inhibitor for acute hereditary angioedema attacks with upper airway involvement
- M.A. Riedl
- H.H. Li
- M. Cicardi
- J.R. Harper
- A. Relan
- Anurag
DOIAbstract
Background: Recombinant human C1 esterase inhibitor (rhC1-INH) is approved for treatment of hereditary angioedema (HAE) in adolescents and adults. HAE attacks that involve the upper airway can be life threatening, and data on the administration of rhC1-INH for these types of attacks are currently limited. Objective: To evaluate the efficacy and safety of rhC1-INH for treatment of acute HAE attacks with upper airway involvement. Methods: A pooled analysis of data from three clinical trials with open-label extensions examined rhC1-INH for treatment of acute HAE attacks with upper airway involvement. Patients with functional plasma C1 esterase inhibitor <50% of normal who had experienced an acute upper airway HAE attack and received ...
Add to ORKG